Physician profile
Dana R Cruse
NPI 1932482874
$108,759.36
in general payments reported to CMS, 2019-2025
27 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $21K · 2023: $17K · 2024: $19K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $14K · Food and Beverage: $11K · Honoraria: $5,950 · Gift: $59.40 · Education: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,712.68 |
| Travel and Lodging | $14,394.33 |
| Food and Beverage | $11,012.52 |
| Honoraria | $5,950.00 |
| Gift | $59.40 |
| Education | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48,236.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $27,575.14 | 2021-2025 | Korlym |
| Mannkind Corporation | $12,570.79 | 2021-2025 | Afrezza, V-Go |
| Astrazeneca Pharmaceuticals Lp | $4,450.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Medtronic, INC. | $4,283.79 | 2021-2024 | Minimed 780g, Minimed 770g |
| Cequr Corporation | $2,809.49 | 2023-2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $2,046.42 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $1,275.91 | 2021-2024 | |
| Lilly USA, LLC | $1,226.29 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $954.61 | 2021-2025 | Omnipod |
| Abbott Laboratories | $856.33 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.86 | 2021-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $370.03 | 2021-2023 | Steglujan, Steglatro, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $303.08 | 2021-2023 | |
| Dexcom, INC. | $257.15 | 2021-2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $188.90 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $154.29 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $139.75 | 2021 | |
| Ironshore Pharmaceuticals INC. | $110.67 | 2023 | Jornay Pm |
| Zealand Pharma US, INC. | $93.36 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $73.55 | 2022 | |
| Sequel Med Tech, LLC | $68.37 | 2025 | Twiist |
| Beta Bionics, INC. | $64.32 | 2024 | Ilet Bionic Pancreas |
| Abbvie INC. | $38.58 | 2022 | |
| Averitas Pharma INC. | $34.91 | 2023-2024 | Qutenza |
| Eusa Pharma (US) LLC | $20.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Cruse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.